Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...

Ten out of 11 children with a form of congenital deafness who were treated with an experimental gene therapy developed by ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: ...

In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...

Elsewhere within Regeneron's product portfolio, Libtayo, a programmed death receptor-1 (PD-1) blocking antibody indicated for non-small cell lung cancer ("NSCLC"), cutaneous squamous cell ...

As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearingSpeech and development ...

Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. Founded in 1988 as a small research firm, Regeneron (NASDAQ:REGN) is a biopharmaceutical company that ...

On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...

MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA," the "Company"), a clinical-stage biopharmaceutical company ...